期刊文献+

西妥昔单抗联合放疗治疗复发性头颈部恶性肿瘤的护理 被引量:2

下载PDF
导出
摘要 目的探讨西妥昔单抗联合放疗治疗复发性头颈部恶性肿瘤的护理方法。方法对5例头颈部恶性肿瘤患者应用西妥昔单抗联合放疗,治疗前给予心理护理,减轻患者焦虑,使其能较好地配合治疗;治疗期间做好心理护理的同时,加强不良反应的护理,预防及减轻不良反应的发生。结果治疗过程中患者均出现不同程度的皮肤反应,经处理后好转,治疗顺利完成。结论恰当的护理措施可预防和减轻西妥昔单抗不良反应的发生,确保治疗顺利进行。
出处 《解放军护理杂志》 2009年第7期36-37,共2页 Nursing Journal of Chinese People's Liberation Army
  • 相关文献

参考文献9

  • 1Bonner J A,Harari. P M,Giralt J, et al Radiotherapy plus eetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2006,354(6) :567-578.
  • 2范丽丽,范晓燕,刘秀峰.西妥昔单抗治疗晚期大肠癌1例的护理体会[J].现代肿瘤医学,2006,14(6):776-776. 被引量:14
  • 3黄雪珍,邹本燕.西妥昔单抗联合化疗治疗转移性结直肠癌的护理[J].中华护理杂志,2007,42(2):157-158. 被引量:23
  • 4Cunningham D, Humblet Y,Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med. 2004,351(4) :337-345.
  • 5Xiong HQ,Rosenberg A,LoBuglio A, et al. Cetuximab,a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase Ⅱ Trial [J].J Clin Oncol, 2004,22 (13) : 2610- 2616.
  • 6Saltz L B, Meropol N J,Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor reeeptor[J].J Clin Oneol, 2004,22(7) :1201-1208.
  • 7Rubin M S, Shin D M,PasmantierM, el al. Monoclonal antibody IMC-225, an antiepidermal growth factor receptor, for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens[J]. Proc Am Soe Clin Oncol, 2000, 19 (2) :231-232.
  • 8时丽丽,康娟.西妥昔单抗致严重过敏反应1例[J].第四军医大学学报,2007,28(1):26-26. 被引量:3
  • 9David C, Yves H,Salvatore Set al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].New Engl J Med,2004,351(4) :337-345.

二级参考文献12

  • 1孔秋焕,邹本燕,刘晓华.美罗华治疗B细胞淋巴瘤并发症的护理[J].现代护理,2004,10(8):725-726. 被引量:9
  • 2安富荣,崔岚,戈升荣.治疗转移性结直肠癌新药——西妥昔单抗[J].中国新药杂志,2005,14(7):927-930. 被引量:20
  • 3储大同,周继昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005.174~182.
  • 4Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Catacer,2001.37(Suppl 4) :16-22.
  • 5Leonard B, Saltz. Neal J. et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology.2004.22(7) : 1201-1208.
  • 6Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation.apoptosis.and radiosensitivity in squamous cell carcinorma of the head and neck. Cancer Res. 1999.59:1935-1940.
  • 7Guslafson NF.Saltz L,Cunningham D.et al. Safety profile of cetuximab in patients with metastatic colorectal cancer. Gastrointestinal Cancers Sympos um 2004 Abstract:237.
  • 8National PBM Drug Monograph Cetuximab (Erbilux^TM). VA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel.2004.1-10.
  • 9Vega-Villegas E, Awada R,Mesia L,et al. A phase Ⅰ study of cetuximab in combination with eisplatin or carhoplatin and 5-FU in patients with recurrent or metastatic squamous cell carcinoma of lhe head and neck. Proceedings of the American Association for Cancer Research,2004, Abstract : 2020.
  • 10Harding J. Burtness B. Cetuximab.. An epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc).2005.41(2):107-127.

共引文献33

同被引文献17

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部